AU721257B2 - Process for preparing 4-aryl-piperidine derivatives - Google Patents

Process for preparing 4-aryl-piperidine derivatives Download PDF

Info

Publication number: AU721257B2
Authority: AU; Australia
Prior art keywords: compound; formula; treatment; viii; optically active
Prior art date: 1995-05-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

AU56845/96A

Other languages

English (en)

Other versions

AU5684596A (en

Inventor

Bjorn Bentzen

Mogens Engelstoft

John Bondo Hansen

Soren Lehmann

Svend Treppendahl

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novo Nordisk AS

Original Assignee

Novo Nordisk AS

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-05-17

Filing date

1996-04-25

Publication date

2000-06-29

1996-04-25 Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS

1996-11-29 Publication of AU5684596A publication Critical patent/AU5684596A/en

2000-06-29 Application granted granted Critical

2000-06-29 Publication of AU721257B2 publication Critical patent/AU721257B2/en

2016-04-25 Anticipated expiration legal-status Critical

Status Ceased legal-status Critical Current

Links

238000004519 manufacturing process Methods 0.000 title claims description 4
150000001875 compounds Chemical class 0.000 claims description 49
239000000203 mixture Substances 0.000 claims description 27
LUSZGTFNYDARNI-UHFFFAOYSA-N Sesamol Chemical compound OC1=CC=C2OCOC2=C1 LUSZGTFNYDARNI-UHFFFAOYSA-N 0.000 claims description 16
238000000034 method Methods 0.000 claims description 14
239000002253 acid Substances 0.000 claims description 10
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 7
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 5
CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 claims description 5
239000003153 chemical reaction reagent Substances 0.000 claims description 4
229910052751 metal Inorganic materials 0.000 claims description 4
239000002184 metal Substances 0.000 claims description 4
238000000746 purification Methods 0.000 claims description 4
238000002425 crystallisation Methods 0.000 claims description 3
229910052739 hydrogen Inorganic materials 0.000 claims description 3
239000001257 hydrogen Substances 0.000 claims description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
238000002360 preparation method Methods 0.000 claims description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
239000003054 catalyst Substances 0.000 claims description 2
238000006243 chemical reaction Methods 0.000 claims description 2
239000007788 liquid Substances 0.000 claims description 2
229910052763 palladium Inorganic materials 0.000 claims description 2
150000003839 salts Chemical class 0.000 claims description 2
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
125000002924 primary amino group Chemical class [H]N([H])* 0.000 claims 1
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 108
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 16
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
238000004296 chiral HPLC Methods 0.000 description 14
239000012071 phase Substances 0.000 description 13
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
239000008346 aqueous phase Substances 0.000 description 12
238000000921 elemental analysis Methods 0.000 description 8
239000003480 eluent Substances 0.000 description 8
229910000027 potassium carbonate Inorganic materials 0.000 description 8
PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 6
238000005160 1H NMR spectroscopy Methods 0.000 description 6
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 6
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 5
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 5
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
229920000858 Cyclodextrin Polymers 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 4
YCDRWGYVEXVMQX-UHFFFAOYSA-N [1-ethyl-4-(4-fluorophenyl)-3,6-dihydro-2h-pyridin-3-yl]methanol Chemical compound OCC1CN(CC)CC=C1C1=CC=C(F)C=C1 YCDRWGYVEXVMQX-UHFFFAOYSA-N 0.000 description 4
HJJPJSXJAXAIPN-UHFFFAOYSA-N arecoline Chemical compound COC(=O)C1=CCCN(C)C1 HJJPJSXJAXAIPN-UHFFFAOYSA-N 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
239000000284 extract Substances 0.000 description 4
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
229960002296 paroxetine Drugs 0.000 description 4
239000000047 product Substances 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
-1 1 -Ethyl-3-hydroxymethyl-4-(4-fluorophenyl)-1, 2 ,3,6-tetrahydropyridine hydrochloride Ethylamine hydrochloride Chemical compound 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
239000000543 intermediate Substances 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
239000011975 tartaric acid Substances 0.000 description 3
235000002906 tartaric acid Nutrition 0.000 description 3
239000012485 toluene extract Substances 0.000 description 3
PTRITADCAOWGKC-UHFFFAOYSA-N (1-methyl-4-phenylpiperidin-3-yl)methanol Chemical compound OCC1CN(C)CCC1C1=CC=CC=C1 PTRITADCAOWGKC-UHFFFAOYSA-N 0.000 description 2
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
238000003747 Grignard reaction Methods 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
230000001430 anti-depressive effect Effects 0.000 description 2
239000000935 antidepressant agent Substances 0.000 description 2
239000002585 base Substances 0.000 description 2
HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
238000001816 cooling Methods 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
239000004210 ether based solvent Substances 0.000 description 2
235000019253 formic acid Nutrition 0.000 description 2
239000012458 free base Substances 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
239000012280 lithium aluminium hydride Substances 0.000 description 2
229910000403 monosodium phosphate Inorganic materials 0.000 description 2
235000019799 monosodium phosphate Nutrition 0.000 description 2
239000012452 mother liquor Substances 0.000 description 2
239000012074 organic phase Substances 0.000 description 2
150000004893 oxazines Chemical class 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
239000007858 starting material Substances 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
230000009466 transformation Effects 0.000 description 2
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
MZLRFUCMBQWLNV-FNORWQNLSA-N (e)-3-(dimethylamino)-1-pyridin-3-ylprop-2-en-1-one Chemical compound CN(C)\C=C\C(=O)C1=CC=CN=C1 MZLRFUCMBQWLNV-FNORWQNLSA-N 0.000 description 1
DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 description 1
SVDDJQGVOFZBNX-UHFFFAOYSA-N 2-chloroethyl carbonochloridate Chemical compound ClCCOC(Cl)=O SVDDJQGVOFZBNX-UHFFFAOYSA-N 0.000 description 1
ROLMZTIHUMKEAI-UHFFFAOYSA-N 4,5-difluoro-2-hydroxybenzonitrile Chemical compound OC1=CC(F)=C(F)C=C1C#N ROLMZTIHUMKEAI-UHFFFAOYSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
ICRPZKBRYZRHLB-UHFFFAOYSA-N 4-methylpentan-2-ol Chemical compound CC(C)CC(C)O.CC(C)CC(C)O ICRPZKBRYZRHLB-UHFFFAOYSA-N 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
208000020401 Depressive disease Diseases 0.000 description 1
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
239000001358 L(+)-tartaric acid Substances 0.000 description 1
235000011002 L(+)-tartaric acid Nutrition 0.000 description 1
FEWJPZIEWOKRBE-LWMBPPNESA-N L-(+)-Tartaric acid Natural products OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
241000288906 Primates Species 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000032683 aging Effects 0.000 description 1
XYLMUPLGERFSHI-UHFFFAOYSA-N alpha-Methylstyrene Chemical compound CC(=C)C1=CC=CC=C1 XYLMUPLGERFSHI-UHFFFAOYSA-N 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
229910000091 aluminium hydride Inorganic materials 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
QOPVNWQGBQYBBP-UHFFFAOYSA-N chloroethyl chloroformate Chemical compound CC(Cl)OC(Cl)=O QOPVNWQGBQYBBP-UHFFFAOYSA-N 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
150000002431 hydrogen Chemical group 0.000 description 1
150000003949 imides Chemical class 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000008517 inhibition of serotonin uptake Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 description 1
231100000189 neurotoxic Toxicity 0.000 description 1
230000002887 neurotoxic effect Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
238000010992 reflux Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000000697 serotonin reuptake Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
230000005062 synaptic transmission Effects 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
238000000844 transformation Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Hydrogenated Pyridines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

AU56845/96A 1995-05-17 1996-04-25 Process for preparing 4-aryl-piperidine derivatives Ceased AU721257B2 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DK563/95		1995-05-17
DK56395		1995-05-17
PCT/DK1996/000185 WO1996036636A1 (en)	1995-05-17	1996-04-25	Process for preparing 4-aryl-piperidine derivatives

Publications (2)

Publication Number	Publication Date
AU5684596A AU5684596A (en)	1996-11-29
AU721257B2 true AU721257B2 (en)	2000-06-29

Family

ID=8094959

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU56845/96A Ceased AU721257B2 (en)	1995-05-17	1996-04-25	Process for preparing 4-aryl-piperidine derivatives

Country Status (11)

Country	Link
EP (1)	EP0828735A1 (de)
JP (1)	JPH11505229A (de)
CN (1)	CN1068597C (de)
AU (1)	AU721257B2 (de)
BR (1)	BR9608471A (de)
CA (1)	CA2220963A1 (de)
HU (1)	HUP9900318A3 (de)
IL (1)	IL118294A0 (de)
NZ (1)	NZ307479A (de)
WO (1)	WO1996036636A1 (de)
ZA (1)	ZA963951B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9526645D0 (en) *	1995-12-28	1996-02-28	Chiroscience Ltd	Stereoselective synthesis
ES2117557B1 (es) *	1996-02-29	1999-07-01	Ferrer Int	Nuevo procedimiento de obtencion de (-)-trans -n-p-fluorobenzoilmetil-4-(p-fluorofenil)-3- ((3,4-(metilendioxi)fenoxi ) metil)-piperidina.
EP1394160A1 (de)	1996-06-13	2004-03-03	SUMIKA FINE CHEMICALS Co., Ltd.	Verfahren zur Herstellung von kristallinem Paroxetin-Hydrochlorid
HU221921B1 (hu) *	1996-07-08	2003-02-28	Richter Gedeon Vegyészeti Gyár Rt.	N-benzil-piperidin- és tetrahidropiridinszármazékok és eljárás azok előállítására
GB9623359D0 (en) *	1996-11-09	1997-01-08	Smithkline Beecham Plc	Novel process
GB9700690D0 (en)	1997-01-15	1997-03-05	Smithkline Beecham Plc	Novel process
GB9710004D0 (en)	1997-05-17	1997-07-09	Knoll Ag	Chemical process
EP0986389B1 (de)	1997-05-29	2004-10-13	Smithkline Beecham Corporation	Neues verfahren
SK283394B6 (sk)	1997-06-10	2003-07-01	Synthon B. V.	Zlúčeniny 4-fenylpiperidínu a jej farmaceuticky prijateľné soli, spôsob ich prípravy, liečivo s ich obsahom a ich použitie
CH689805A8 (fr) *	1998-07-02	2000-02-29	Smithkline Beecham Plc	Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
GB9826175D0 (en) *	1998-11-28	1999-01-20	Smithkline Beecham Plc	Novel process
GB9828767D0 (en) *	1998-12-29	1999-02-17	Smithkline Beecham Plc	Novel process
IT1308629B1 (it) *	1999-02-23	2002-01-09	Recordati Chem Pharm	Processo per la produzione di paroxetina.
IT1313702B1 (it) *	1999-08-02	2002-09-09	Chemi Spa	Processo per la preparazione di derivati 3-sostituiti di 4-fenil-piperidine.
AU1018801A (en) *	1999-10-29	2001-05-14	Novo Nordisk A/S	Use of 3,4-substituted piperidines
GB9930577D0 (en) *	1999-12-23	2000-02-16	Smithkline Beecham Plc	Novel process
CZ20023694A3 (cs)	2000-05-12	2003-05-14	Synthon B. V.	Tosylátové soli 4-(p-fluorfenyl)-piperidin-3-methanolů
EP1301508A1 (de) *	2000-07-17	2003-04-16	Smithkline Beecham Plc	Verfahren zur herstellung von 4-phenylpiperidin-derivate
GB0021145D0 (en) *	2000-08-30	2000-10-11	Knoll Ag	Chemical process
GB0021147D0 (en)	2000-08-30	2000-10-11	Knoll Ag	Chemical process
WO2002028834A1 (en) *	2000-10-06	2002-04-11	Smithkline Beecham P.L.C.	Process for the preparation of aryl-piperidine carbinols and intermediates thereof
EP1347960B1 (de) *	2001-01-04	2004-11-17	Ferrer Internacional, S.A.	Verfahren zur herstellung von (+)-trans-4-p-fluorophenyl-3-hydroxymethyl-1-methylpiperidin
WO2015071831A1 (en) *	2013-11-18	2015-05-21	Piramal Enterprises Limited	An improved process for minimising the formation of dehalogenated byproducts
CN117447454B (zh) *	2023-10-07	2026-02-06	重庆普佑生物医药有限公司	一种盐酸帕罗西汀的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1422263A (en) *	1973-01-30	1976-01-21	Ferrosan As	4-phenyl-piperidine compounds
US4593036A (en) *	1984-02-07	1986-06-03	A/S Ferrosan	(-)-Trans-4-(4-fluorophenyl)-3-[(4-methoxyphenoxy)methyl]-1-methylpiperidine useful as 5-HT potentiator
IE66332B1 (en) *	1986-11-03	1995-12-27	Novo Nordisk As	Piperidine compounds and their preparation and use
DK715988D0 (da) *	1988-12-22	1988-12-22	Ferrosan As	Etherifikation og dealkylering af piperidin-derivater samt intermediater

1996
- 1996-04-25 CN CN96193942A patent/CN1068597C/zh not_active Expired - Fee Related
- 1996-04-25 HU HU9900318A patent/HUP9900318A3/hu unknown
- 1996-04-25 JP JP8534464A patent/JPH11505229A/ja active Pending
- 1996-04-25 EP EP96914861A patent/EP0828735A1/de not_active Ceased
- 1996-04-25 WO PCT/DK1996/000185 patent/WO1996036636A1/en not_active Ceased
- 1996-04-25 AU AU56845/96A patent/AU721257B2/en not_active Ceased
- 1996-04-25 CA CA002220963A patent/CA2220963A1/en not_active Abandoned
- 1996-04-25 BR BR9608471A patent/BR9608471A/pt not_active Application Discontinuation
- 1996-04-25 NZ NZ307479A patent/NZ307479A/xx unknown
- 1996-05-16 IL IL11829496A patent/IL118294A0/xx unknown
- 1996-05-17 ZA ZA963951A patent/ZA963951B/xx unknown

Also Published As

Publication number	Publication date
ZA963951B (en)	1997-01-21
IL118294A0 (en)	1996-09-12
HUP9900318A3 (en)	2001-09-28
AU5684596A (en)	1996-11-29
CN1184476A (zh)	1998-06-10
WO1996036636A1 (en)	1996-11-21
NZ307479A (en)	1999-08-30
EP0828735A1 (de)	1998-03-18
CA2220963A1 (en)	1996-11-21
JPH11505229A (ja)	1999-05-18
CN1068597C (zh)	2001-07-18
BR9608471A (pt)	1998-12-29
HUP9900318A2 (hu)	1999-09-28

Legal Events

Date	Code	Title	Description
2000-10-26	FGA	Letters patent sealed or granted (standard patent)
2003-11-27	MK14	Patent ceased section 143(a) (annual fees not paid) or expired

Publication	Publication Date	Title
AU721257B2 (en)	2000-06-29	Process for preparing 4-aryl-piperidine derivatives
WO2009056791A1 (en)	2009-05-07	Processes for preparing pharmaceutical compounds
IE862802L (en)	1987-04-25	Crystalline paroxetine
JP2007231024A (ja)	2007-09-13	３，３−ジアリルプロピルアミンの製造プロセス
WO1995031456A1 (en)	1995-11-23	Process for the preparation of azabicyclic derivatives
US20090182156A1 (en)	2009-07-16	Synthesis and preparations of duloxetine salts
JPH05221982A (ja)	1993-08-31	４‐アミノメチルピペリジン誘導体、その製造および治療への応用
EP1384722A8 (de)	2004-09-08	Verfahren zur Herstellung von 2-(5-Methyl-4-oxazolyl)acetates
JP2546624B2 (ja)	1996-10-23	光学的に純粋なアミノアルコールの製造方法
US5880296A (en)	1999-03-09	Method for preparing an optically pure benzofuran carboxylic acid and use thereof for preparing efaroxan
EP1153023B1 (de)	2003-04-23	Verfahren zur herstellung von paroxetin
US6444822B1 (en)	2002-09-03	Process for the preparation of 3-substituted 4-phenyl-piperidine derivative
KR100275978B1 (ko)	2000-12-15	(-)-n-메틸-n-(4-(4-페닐-4-아세틸아미노피페리딘-1-일)-2-(3,4-디클로로페닐)부틸)벤즈아미드 및 약학적으로 허용가능한 그의 염의 제조방법
US20100261775A1 (en)	2010-10-14	Polymorphic form of duloxetine hydrochloride
WO2002020461A1 (en)	2002-03-14	3-amino-1-indanole, method of synthesizing the same and method of optical resolution
US6150417A (en)	2000-11-21	Phenoxyethylamine derivatives, method of preparation application as medicine and pharmaceutical compositions containing same
CN121358709A (zh)	2026-01-16	用于制备5-{2-[苄基-(1-(4-羟基苯基)-1-甲基乙基)氨基]-1-羟基乙基}苯-1,3-二醇半富马酸盐的方法
HK1012367B (en)	2004-04-16	Process for the preparation of azabicyclic derivatives